Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 761908, 8 pages
http://dx.doi.org/10.1155/2015/761908
Research Article

Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer

Department of Oncology and Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia

Received 23 July 2015; Accepted 2 November 2015

Academic Editor: Hamid Raziee

Copyright © 2015 Oleg Kurtenkov and Kersti Klaamas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. M. Abd Hamid, L. Royle, R. Saldova et al., “A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression,” Glycobiology, vol. 18, no. 12, pp. 1105–1118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Dall'Olio, N. Malagolini, M. Trinchera, and M. Chiricolo, “Mechanisms of cancer-associated glycosylation changes,” Frontiers in Bioscience, vol. 17, no. 2, pp. 670–699, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Hakomori, “Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens,” Advances in Cancer Research, vol. 52, pp. 257–331, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Kobold, T. Lütkens, Y. Cao, C. Bokemeyer, and D. Atanackovic, “Autoantibodies against tumor-related antigens: incidence and biologic significance,” Human Immunology, vol. 71, no. 7, pp. 643–651, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Maverakis, K. Kim, M. Shimoda et al., “Glycans in the immune system and the altered glycan theory of autoimmunity: a critical review,” Journal of Autoimmunity, vol. 57, pp. 1–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Radhakrishnan, S. Dabelsteen, F. B. Madsen et al., “Immature truncated O-glycophenotype of cancer directly induces oncogenic features,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 39, pp. E4066–E4075, 2014. View at Publisher · View at Google Scholar
  7. G. F. Springer, “T and Tn, general carcinoma autoantigens,” Science, vol. 224, no. 4654, pp. 1198–1206, 1984. View at Publisher · View at Google Scholar · View at Scopus
  8. T.-T. Tan and L. M. Coussens, “Humoral immunity, inflammation and cancer,” Current Opinion in Immunology, vol. 19, no. 2, pp. 209–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. H. H. Wandall, O. Blixt, M. A. Tarp et al., “Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes,” Cancer Research, vol. 70, no. 4, pp. 1306–1313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. W. R. Alley, J. A. Vasseur, J. A. Goetz et al., “N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients,” Journal of Proteome Research, vol. 11, no. 4, pp. 2282–2300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. N. Arnold, R. Saldova, M. C. Galligan et al., “Novel glycan biomarkers for the detection of lung cancer,” Journal of Proteome Research, vol. 10, no. 4, pp. 1755–1764, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. R. R. Drake, E. E. Schwegler, G. Malik et al., “Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers,” Molecular and Cellular Proteomics, vol. 5, no. 10, pp. 1957–1967, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kodar, O. Kurtenkov, and K. Klaamas, “The thomsen-friedenreich antigen and αGal-specific human IgG glycoforms: concanavalin a reactivity and relation to survival of cancer patients,” Immunological Investigations, vol. 38, no. 8, pp. 704–717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Kodar, J. Stadlmann, K. Klaamas, B. Sergeyev, and O. Kurtenkov, “Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival,” Glycoconjugate Journal, vol. 29, no. 1, pp. 57–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Kodar, J. Izotova, K. Klaamas, B. Sergeyev, L. Järvekülg, and O. Kurtenkov, “Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients,” World Journal of Gastroenterology, vol. 19, no. 23, pp. 3573–3582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. E. Baldus, T. K. Zirbes, F.-G. Hanisch et al., “Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: a clinicopathologic study of 264 patients,” Cancer, vol. 88, no. 7, pp. 1536–1543, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. G. F. Springer, “Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy,” Journal of Molecular Medicine, vol. 75, no. 8, pp. 594–602, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. L.-G. Yu, “The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression,” Glycoconjugate Journal, vol. 24, no. 8, pp. 411–420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. W.-M. Lin, U. Karsten, S. Goletz, R.-C. Cheng, and Y. Cao, “Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells,” International Journal of Experimental Pathology, vol. 92, no. 2, pp. 97–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Almogren, J. Abdullah, K. Ghapure, K. Ferguson, V. V. Glinsky, and K. Rittenhouse-Olson, “Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy,” Frontiers in Bioscience, vol. 4, no. 3, pp. 840–863, 2012. View at Google Scholar · View at Scopus
  21. M. M. Fuster and J. D. Esko, “The sweet and sour of cancer: glycans as novel therapeutic targets,” Nature Reviews Cancer, vol. 5, no. 7, pp. 526–542, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Schwartz-Albiez, S. Laban, S. Eichmüller, and M. Kirschfink, “Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?” Autoimmunity Reviews, vol. 7, no. 6, pp. 491–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. G. F. Springer, P. R. Desai, B. D. Spencer, H. Tegtmeyer, S. C. Carlstedt, and E. F. Scanlon, “T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma,” Cancer Detection and Prevention, vol. 19, no. 4, pp. 374–380, 1995. View at Google Scholar · View at Scopus
  24. P. R. Desai, “Immunoreactive T and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy,” Transfusion Medicine Reviews, vol. 14, no. 4, pp. 312–325, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Kurtenkov, K. Klaamas, and L. Miljukhina, “The lower level of natural anti-Thomsen-Friedenreich Antigen (TFA) agglutinins in sera of patients with gastric cancer related to ABO(H) blood-group phenotype,” International Journal of Cancer, vol. 60, no. 6, pp. 781–785, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. O. Kurtenkov, K. Klaamas, S. Mensdorff-Pouilly, L. Miljukhina, L. Shljapnikova, and V. Chužmarov, “Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival,” Acta Oncologica, vol. 46, no. 3, pp. 316–323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Kurtenkov, L. Miljukhina, J. Smorodin et al., “Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors—relation to Lewis (a,b) histo-blood group phenotype,” Acta Oncologica, vol. 38, no. 7, pp. 939–943, 1999. View at Publisher · View at Google Scholar
  28. C. Schindlbeck, U. Jeschke, S. Schulze et al., “Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients,” Breast Cancer Research and Treatment, vol. 101, no. 1, pp. 17–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. P. Smorodin, O. A. Kurtenkov, B. L. Sergeyev, K. E. Kodar, V. I. Chuzmarov, and V. P. Afanasyev, “Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4352–4358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. V. V. Glinsky, G. V. Glinsky, K. Rittenhouse-Olson et al., “The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium,” Cancer Research, vol. 61, no. 12, pp. 4851–4857, 2001. View at Google Scholar · View at Scopus
  31. J. Heimburg, J. Yan, S. Morey et al., “Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody. JAA-F11,” Neoplasia, vol. 8, no. 11, pp. 939–948, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Nimmerjahn and J. V. Ravetch, “Antibodies, Fc receptors and cancer,” Current Opinion in Immunology, vol. 19, no. 2, pp. 239–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Johansson, D. G. DeNardo, and L. M. Coussens, “Polarized immune responses differentially regulate cancer development,” Immunological Reviews, vol. 222, no. 1, pp. 145–154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. L.-G. Yu, B. Jansson, D. G. Fernig et al., “Stimulation of proliferation in human colon cancer cells by human monoclonal antibodies against the TF antigen (galactose β1-3 N-acetyl- galactosamine),” International Journal of Cancer, vol. 73, no. 3, pp. 424–431, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Espy, W. Morelle, N. Kavian et al., “Sialylation levels of anti–proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's),” Arthritis and Rheumatism, vol. 63, no. 7, pp. 2105–2115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Kurtenkov, J. Izotova, K. Klaamas, and B. Sergeyev, “Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential,” BioMed Research International, vol. 2014, Article ID 830847, 11 pages, 2014. View at Publisher · View at Google Scholar
  37. M. Oaks, S. Taylor, and J. Shaffer, “Autoantibodies targeting tumor-associated antigens in metastatic cancer Sialylated iggs as candidate anti-inflammatory antibodies,” OncoImmunology, vol. 2, no. 6, Article ID e24841, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. Ç. Gerçel-Taylor, L. B. Bazzett, and D. D. Taylor, “Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer,” Gynecologic Oncology, vol. 81, no. 1, pp. 71–76, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Nimmerjahn and J. V. Ravetch, “Analyzing antibody-Fc-receptor interactions,” Methods in Molecular Biology, vol. 415, pp. 151–162, 2008. View at Google Scholar · View at Scopus
  41. T. S. Raju, “Terminal sugars of Fc glycans influence antibody effector functions of IgGs,” Current Opinion in Immunology, vol. 20, no. 4, pp. 471–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Smorodin, B. Sergeyev, K. Klaamas, V. Chuzmarov, and O. Kurtenkov, “The relation of the level of serum anti-TF, -Tn and -alpha-gal IgG to survival in gastrointestinal cancer patients,” International Journal of Medical Sciences, vol. 10, no. 12, pp. 1674–1682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. H. P. Vollmers and S. Brändlein, “Natural antibodies and cancer,” Journal of Autoimmunity, vol. 29, no. 4, pp. 295–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Stadlmann, A. Weber, M. Pabst et al., “A close look at human IgG sialylation and subclass distribution after lectin fractionation,” Proteomics, vol. 9, no. 17, pp. 4143–4153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Harduin-Lepers, M.-A. Krzewinski-Recchi, F. Colomb, F. Foulquier, S. Groux-Degroote, and P. Delannoy, “Sialyltransferases functions in cancers,” Frontiers in Bioscience—Elite, vol. 4, no. 1, pp. 499–515, 2012. View at Google Scholar · View at Scopus
  46. J.-J. Park and M. Lee, “Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer,” Gut and Liver, vol. 7, no. 6, pp. 629–641, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. M. J. Pelak, B. Jarosz, A. Straczynska-Niemiec et al., “The presence and clinical implications of α-2,6-galactose-linked sialic acids in non-small-cell lung cancer brain metastases—preliminary study,” Folia Histochemica et Cytobiologica, vol. 52, no. 2, pp. 104–111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Böhm, I. Schwab, A. Lux, and F. Nimmerjahn, “The role of sialic acid as a modulator of the anti-inflammatory activity of IgG,” Seminars in Immunopathology, vol. 34, no. 3, pp. 443–453, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Raman, P. J. Baugher, Y. M. Thu, and A. Richmond, “Role of chemokines in tumor growth,” Cancer Letters, vol. 256, no. 2, pp. 137–165, 2007. View at Publisher · View at Google Scholar · View at Scopus